Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_assertion type Assertion NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_head.
- NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_assertion description "[We have found that (i) established EOC tumour cell lines expressed transcripts for transforming growth factor-beta 2 (TGF-beta2) (7/7), but not IL-10 (0/7) or interferon-gamma (IFN-gamma) (0/7) and rarely IL-2 (1/7); (ii) PEC expressed transcripts for IL-2 (12/13), IL-10 (9/13), and TGF-beta2 (12/13), and less often, IFN-gamma (3/13), whereas solid tumour specimens from eight patients with EOC expressed transcripts for IL-2 (4/8), TGF-beta2 (4/8), and IL-10 (5/8), but not for IFN-gamma (0/8); (iii) CD4+ TCRalphabeta+ T cell lines expressed transcripts for IFN-gamma (4/4), IL-2 (4/4) and IL-10 (3/4), whereas CD8+ TCRalphabeta+ T cell lines expressed transcripts for IFN-gamma (5/5), IL-2 (1/5) and IL-10 (2/5).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_provenance.
- NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_assertion evidence source_evidence_literature NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_provenance.
- NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_assertion SIO_000772 9649178 NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_provenance.
- NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_assertion wasDerivedFrom befree-20140225 NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_provenance.
- NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_assertion wasGeneratedBy ECO_0000203 NP531057.RATPf6iPRhEnr-k5WohoIpowq0N3BtIi56njaRNEExzHg130_provenance.